<DOC>
	<DOCNO>NCT01018940</DOCNO>
	<brief_summary>To determine prasugrel superior clopidogrel provide adequate antiplatelet effect high risk population require concomitant use Proton Pump Inhibitor ( PPI ) .</brief_summary>
	<brief_title>Influence Proton Pump Inhibitor Omeprazole Anti-Platelet P2Y12 Antagonists Subjects With Coronary Peripheral Artery Disease</brief_title>
	<detailed_description>To evaluate simultaneous treatment PPI omeprazole P2Y12 receptor antagonist influence effect either clopidogrel and/or prasugrel platelet reactivity patient Coronary Artery Disease ( CAD ) Peripheral Arterial Disease ( PAD ) .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Proton Pump Inhibitors</mesh_term>
	<mesh_term>Omeprazole</mesh_term>
	<criteria>Adults 18 75 year age Known documented history CAD PAD prior enrollment ( diagnosis CAD may base upon positive stress test , prior document acute coronary event , angiographic demonstration CAD ; diagnosis PAD may base upon anklebrachial index less 0.9 , angiographic demonstration PAD ) Have thienopyridine therapy least 15 day study Have treatment PPI least 15 day study Are take aspirin ( 75 325 mg/day ) least one week prior randomization Have New York Heart association ( NYHA ) Class III IV congestive heart failure Have form coronary revascularization ( PCI coronary artery bypass graft [ CABG ] ) plan occur study Have undergo PCI CABG within 30 day entry study Have receive drug elute endovascular stent past year Have following : 1 . Prior history hemorrhagic stroke transient ischemic attack ( TIA ) 2 . Intracranial neoplasm , arteriovenous malformation , aneurysm 3 . A body weight le 60 kg Have prior history GI ulcer disease bleed Have symptom dyspepsia gastroesophageal reflux disease Have active internal bleeding history bleed diathesis Have clinical finding , judgment investigator , associate increase risk bleeding Have International Normalized Ratio ( INR ) know &gt; 1.5 time evaluation Have platelet count &lt; 100,000/mm3 time screening , know Have anemia ( hemoglobin [ Hgb ] &lt; 10 gm/dL ) time screening , know Are receive receive oral anticoagulation antiplatelet therapy ( aspirin ) safely discontinue duration study Are receive daily treatment nonsteroidal antiinflammatory drug ( NSAIDs ) discontinue require daily treatment NSAIDs study . Are receive corticosteroid therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>